Late Cardiotoxicity in MS Patients Treated with Mitoxantrone

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Mitoxantrone (MTX) is an anthracycline drug used for refractory multiple sclerosis (MS).
• Congestive heart failure (CHF) is a rare complication of MTX, occurring early or late after treatment initiation.
• Evaluating long-term cardiac effects of MTX is essential due to potential cardiotoxicity.

Purpose of the Study:

• To assess the long-term impact of Mitoxantrone (MTX) on cardiac function in multiple sclerosis (MS) patients.
• To determine the incidence of left ventricular (LV) systolic and diastolic dysfunction following MTX therapy.
• To establish the risk of early and late-onset cardiac complications in MS patients treated with MTX.

Main Methods:

• A cohort of 49 multiple sclerosis (MS) patients receiving Mitoxantrone (MTX) therapy was studied.
• Left ventricular (LV) systolic and diastolic functions were assessed using echocardiography.
• Baseline echocardiographic data were compared with post-treatment evaluations by a single cardiologist.

Main Results:

• A significant increase in the probability of developing systolic dysfunction was observed (P < 0.001).
• One patient (2%) experienced a reduction in ejection fraction (EF) below 50%.
• Two patients (4%) developed diastolic dysfunction despite normal baseline function.

Conclusions:

• Mitoxantrone (MTX) therapy increases the risk of early and late left ventricular (LV) dysfunction in multiple sclerosis (MS) patients.
• Regular cardiac monitoring is recommended for all MS patients undergoing MTX treatment to detect potential complications.
• Early identification and management of MTX-induced cardiotoxicity are vital for patient outcomes.